CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD
Globe Newswire•08/11/2026•16:00 ET
0
Key Highlights
- ➤CIDEB(siRNA) cut liver fat 58-80% at week 36, dose-dependent
- ➤62% of recipients normalized liver fat versus none on placebo
- ➤93% achieved liver-fat reductions of at least 30% at week 36
- ➤Adverse events were generally similar; no trial discontinuations occurred
- ➤Regeneron is advancing CIDEB(siRNA) through recruiting Phase 2a, 2b and 3 trials
Expert Statements
Jörg Täubel, Executive Chairman of Richmond Pharmacology, Visiting Professor at King’s College London, Honorary Senior Research Fellow at St. George’s University in London, President of The Association for Applied Human Pharmacology, and lead investigator for the trial
“These results show CIDEB(siRNA) resulted in rapid, deep and sustained reductions in liver fat with improvements in markers of liver injury. With effects out to 36 weeks that support the potential for twice-yearly dosing, alongside the safety profile, the findings highlight CIDEB(siRNA) as a promising new therapeutic for MASH and other steatotic liver diseases.”
Single administration of CIDEB(siRNA) resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks
Data from first-in-human trial were shared in oral presentation at AASLD The Liver Meeting(® )and simultaneously published in The New England Journal of Medicine
Get started
Create a free account to read the full story.